Acromegaly improved with sandostatin LAR treatment.
- Author:
Young Ju LEE
1
;
Hyun Chul JO
;
Seung Hyung HA
;
Ji Wong JANG
;
Jong Hwa KIM
;
Heung Kon HWANG
Author Information
1. Department of Internal Medicine, Sejong Hospital, Bucheon, Korea. grimza5@naver.com
- Publication Type:Case Report
- Keywords:
Acromegaly;
Dilated cardiomyopathy
- MeSH:
Acromegaly*;
Cardiomyopathy, Dilated;
Cardiovascular Diseases;
Cause of Death;
Echocardiography;
Female;
Follow-Up Studies;
Growth Hormone;
Humans;
Insulin;
Octreotide*;
Somatostatin
- From:Korean Journal of Medicine
2007;73(6):643-646
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Cardiovascular disease is the most frequent cause of death in patients with acromegaly. Recently, long-term treatment with a somatostatin analogue (Sandostatin LAR) has been shown to be effective in controlling growth hormone (GH) and insulin like growth factor-1 (IGF-1) hypersecretion in most patients with acromegaly. Along with the effectiveness in the hormone profile, Sandostatin LAR has been reported to be effective for tumor mass shrinkage and clinical symptom improvement. We have encountered a female acromeglic patient with severe dilated cardiomyopathy and the patient was treated with Sandostatin LAR After treatment for 12 months, as seen by follow up echocardiography, the overall cardiac function was significantly improved. We report the case with a review of the literature.
